Laughable, Merck has access to all the UCLA trial data passed on DCVax-L and just both another Glioblastoma treatment for $30 mil upfront and a potential of over $1 Billion. Get real.
Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers
Lei Lei Wu Endpoints News Reporter
Merck is acquiring a startup spun out of Yale called Modifi Bio, which has developed a suite of molecules against chemotherapy-resistant glioblastoma, a devastating and often deadly disease.
Merck will pay $30 million upfront, and the deal could be worth as much as $1.3 billion based on potential future payments.
Modifi Bio was founded in 2021 in hopes of turning the academic findings from Yale scientists into a new treatment for brain cancers. That research, published in Science when the company launched in 2022, showed that a so-called DNA modifier could essentially link two strands of DNA in a way slow enough that healthy cells could reverse any damage, but cancer cells couldn’t, leading only cancer cells to die.
Market Data 
Markets 
AI
